51. HPV Vaccination in Children With JIA
- Author
-
Suzanne Li
- Subjects
Pediatrics ,medicine.medical_specialty ,biology ,business.industry ,Immunogenicity ,Arthritis ,Hpv vaccination ,medicine.disease ,Vaccination ,Immunology ,biology.protein ,General Earth and Planetary Sciences ,Medicine ,Cervarix ,Antibody ,business ,Memory B cell ,General Environmental Science - Abstract
Dr Li has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. Researchers from The Netherlands recently evaluated the efficacy and safety of the bivalent HPV vaccine (Cervarix) administered at 0, 1, and 6 months in females aged 12 to 18 years with juvenile idiopathic arthritis [JIA] compared to healthy controls (HC).1 Immunogenicity was determined by measuring the level of HPV-specific IgG antibodies (reported as geometric mean concentration [GMC]) to calculate the seropositivity rate at 7 and 12 months after the first vaccination. Investigators also measured memory B cell responses before the first vaccination and 3, 7, and 12 months afterwards in a subset of JIA and …
- Published
- 2014